NLM Digital Collections

Search

Start Over Subjects Immunologic Factors -- economics ✖Remove constraint Subjects: Immunologic Factors -- economics

1. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value : final evidence report

Publication:
Boston, MA : Institute for Clinical and Economic Review, December 2 2016
Subject(s):
Comparative Effectiveness Research
Immunologic Factors -- therapeutic use
Psoriasis -- drug therapy
Adalimumab -- therapeutic use
Benchmarking
Etanercept -- therapeutic use
Immunologic Factors -- adverse effects
Immunologic Factors -- economics
Interleukin-12 -- antagonists & inhibitors
Interleukin-17
Interleukin-23 -- antagonists & inhibitors
Phosphodiesterase 4 Inhibitors
Phototherapy
Psoriasis -- immunology
Psoriasis -- therapy
Randomized Controlled Trials as Topic
Severity of Illness Index
Tumor Necrosis Factor-alpha -- antagonists & inhibitors
Ustekinumab -- therapeutic use
Value-Based Purchasing
Humans
United States

2. Targeted immune modulators for rheumatoid arthritis: effectiveness & value : evidence report

Publication:
Boston, MA : Institute for Clinical and Economic Review, March 10, 2017
Subject(s):
Arthritis, Rheumatoid -- drug therapy
Comparative Effectiveness Research
Immunologic Factors -- therapeutic use
Abatacept -- therapeutic use
Adalimumab -- therapeutic use
Certolizumab Pegol -- therapeutic use
Cost-Benefit Analysis
Etanercept -- therapeutic use
Immunologic Factors -- adverse effects
Immunologic Factors -- economics
Immunotherapy
Infliximab -- therapeutic use
Interleukin-6 -- antagonists & inhibitors
Protein Kinase Inhibitors -- therapeutic use
Randomized Controlled Trials as Topic
Rituximab -- therapeutic use
Treatment Outcome
Tumor Necrosis Factor-alpha -- antagonists & inhibitors
Value-Based Purchasing
Humans
United States

3. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value : condition update : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, August 3, 2018
Subject(s):
Immunologic Factors -- therapeutic use
Immunomodulation
Psoriasis -- drug therapy
Certolizumab Pegol -- therapeutic use
Clinical Trials as Topic
Cost-Benefit Analysis
Immunologic Factors -- adverse effects
Immunologic Factors -- economics
Quality of Life
Treatment Outcome
Humans
United States